These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 409785)

  • 21. Amikacin therapy. Use against infections caused by gentamicin- and tobramycin-resistant organisms.
    Yu VL; Rhame FS; Pesanti EL; Axline SG
    JAMA; 1977 Aug; 238(9):943-7. PubMed ID: 328950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amikacin therapy of gram-negative bacteremia and meningitis. Treatment in diseases due to multiple resistant bacilli.
    Sklaver AR; Greenman RL; Hoffman TA
    Arch Intern Med; 1978 May; 138(5):713-6. PubMed ID: 348135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term amikacin use. Effects on aminoglycoside susceptibility patterns of gram-negative bacilli.
    Moody MM; de Jongh CA; Schimpff SC; Tillman GL
    JAMA; 1982 Sep; 248(10):1199-202. PubMed ID: 6809965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Fundamental and clinical studies on amikacin (BB-K8) in complicated urinary tract infections (author's transl)].
    Mita T; Mayumi K; Kataoka N; Ishigami J
    Jpn J Antibiot; 1977 Mar; 30(3):215-22. PubMed ID: 404447
    [No Abstract]   [Full Text] [Related]  

  • 25. Bactericidal activity of amikacin and gentamicin.
    Shah RM; Heetderks G; Stille W
    Chemotherapy; 1977; 23(4):260-6. PubMed ID: 405182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro susceptibility of recently isolated gram-negative bacteria to gentamicin, sisomicin, tobramycin, and amikacin.
    Knothe H
    J Infect Dis; 1976 Nov; 134 SUPPL():S271-4. PubMed ID: 825585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endemic resistance to amikacin among hospital isolates of gram-negative bacilli: implications for therapy.
    Wormser GP; Tatz J; Donath J
    Infect Control; 1983; 4(2):93-9. PubMed ID: 6404852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparison of the antibacterial activity of amikacin (BB-K8) with other aminoglycosides against pathogens recently isolated from clinical materials (author's transl) ].
    Kosakai N; Oguri T
    Jpn J Antibiot; 1975 Aug; 28(4):530-7. PubMed ID: 240047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Susceptibility of recently isolated bacteria to amikacin in vitro: comparisons with four other aminoglycoside antibiotics.
    Finland M; Garner C; Wilcox C; Sabath LD
    J Infect Dis; 1976 Nov; 134 SUPPL():S297-307. PubMed ID: 825588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and microbiologic consequences of amikacin use during a 42-month period.
    Berk SL; Alvarez S; Ortega G; Verghese A; Holtsclaw-Berk SA
    Arch Intern Med; 1986 Mar; 146(3):538-41. PubMed ID: 3954526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of amikacin and ten other aminoglycoside antibiotics against gentamicin-resistant bacterial strains.
    Reyonolds AV; Hamilton-Miller JM; Brumfitt W
    J Infect Dis; 1976 Nov; 134 SUPPL():S291-6. PubMed ID: 62815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparison of bactericidal effects of four aminoglycoside antibiotics: amikacin, gentamicin, kanamycin and tobramycin (author's transl)].
    Drugeon HB; Courtieu AL
    Ann Microbiol (Paris); 1979 Apr; 130A(3):331-43. PubMed ID: 114083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amikacin therapy of patients with multiply antibiotic-resistant Serratia marcescens infections: development of increasing resistance during therapy.
    Craven PC; Jorgensen JH; Kaspar RL; Drutz DJ
    Am J Med; 1977 Jun; 62(6):902-10. PubMed ID: 326046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparative activity of habekacin and 4 other aminoglycosides against gram-negative bacilli. Evolution of resistance].
    Reynaud AE; Coude du Foresto B; Derriennic M; Courtieu AL
    Pathol Biol (Paris); 1988 May; 36(5):435-8. PubMed ID: 3136424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. R plasmids coding for gentamicin, tobramycin, and carbenicillin resistance in Serratia, Klebsiella and Escherichia coli strains from a single clinical source.
    Knothe H; Kettner M; Kopsová D; Krcméry V
    Chemotherapy; 1977; 23(1):37-43. PubMed ID: 401718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of clindamycin on the in vitro activity of amikacin and gentamicin against gram-negative bacilli.
    Zinner SH; Provonchee RB; Elias KS; Peter G
    Antimicrob Agents Chemother; 1976 Apr; 9(4):661-4. PubMed ID: 817663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of amikacin at sub-inhibitory levels.
    Shah PM; Heetderks G; Stille W
    J Antimicrob Chemother; 1976 Mar; 2(1):97-100. PubMed ID: 819413
    [No Abstract]   [Full Text] [Related]  

  • 38. Newer aminoglycosides--amikacin and tobramycin: an in-vitro comparison with kanamycin and gentamicin.
    Reynolds AV; Hamilton-Miller JM; Brumfitt W
    Br Med J; 1974 Sep; 3(5934):778-80. PubMed ID: 4213265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical, epidemiologic and microbiologic features of a persistent outbreak of amikacin-resistant Serratia marcescens.
    Arroyo JC; Milligan WL; Postic B; Northey J; Parker E; Bryan CS
    Infect Control; 1981; 2(5):367-72. PubMed ID: 7028654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum bactericidal activity of ceftazidime and cefoperazone alone or in combination with amikacin against Pseudomonas aeruginosa and Klebsiella pneumoniae.
    Van Laethem Y; Lagast H; Klastersky J
    Antimicrob Agents Chemother; 1983 Mar; 23(3):435-9. PubMed ID: 6221694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.